{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:14:16Z","timestamp":1762866856277},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of anti\u2010hepatitis C virus (HCV)antibodies is higher in hemodialysis patients than in the general population, and several studies have reported poor vital prognosis in HCV\u2010infected dialysis patients because infection with HCV is not only the cause of cirrhosis and hepatocellular carcinoma, but also a risk factor for cardiovascular disease. Although sustained virologic response (SVR) is achievable with interferon and ribavirin in dialysis patients, SVR rates are lower, and the use of ribavirin is challenging because of the risk of hemolytic anemia. Recently, interferon\u2010ribavirin free direct acting antivirals (DAAs) treatment has shown strong efficacy and fewer adverse events for chronic HCV infection patients without using dialysis, but there are few reports about DAAs for such patients. Thus, we conducted a study to examine the effect and safety of daclatasvir and asunaprevir in chronic hepatitis C virus genotype 1b\u2010infected hemodialysis patients. We treated 10 patients: seven males and three females. Before treatment, we detected resistance\u2010associated variants on the NS5A region, which is the L31M site variant, in two patients. Although two patients showed resistance\u2010associated variant, all the patients showed quick disappearance of HCV RNA in the serum and achieved a SVR12. During this therapy, no patients displayed abnormal liver function during treatment. Two patients experienced diarrhea and another one patient complained of nausea soon after treatment but these were relieved by symptomatic therapy. We report good results of treatment for chronic hepatitis C virus genotype 1b \u2010infected patients on hemodialysis with all oral DAAs (daclatasvir and asunaprevir).<\/jats:p>","DOI":"10.1111\/1744-9987.12407","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T13:19:56Z","timestamp":1461244796000},"page":"462-467","source":"Crossref","is-referenced-by-count":25,"title":["Effect and Safety of Daclatasvir\u2010Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b \u2010Infected Patients on Hemodialysis"],"prefix":"10.1111","volume":"20","author":[{"given":"Ryoichi","family":"Miyazaki","sequence":"first","affiliation":[{"name":"Fujita Memorial Hospital Internal Medicine  Fukui Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Miyagi","sequence":"additional","affiliation":[{"name":"Fujita Memorial Hospital Internal Medicine  Fukui Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15109-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i3.548"},{"key":"e_1_2_6_4_1","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, evaluation and treatment of hepatitis C in chronic kidney disease","volume":"73","year":"2008","journal-title":"Kidney Int"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00828-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2009.00789.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V11101896"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.07.004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070736"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2012.01078.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01780.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00907.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27113"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26388"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12413"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.455"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.019"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12189"},{"key":"e_1_2_6_23_1","unstructured":"KhatriA DuttaS MarburyTet al.The pharmacokinetics and safety of the direct acting antiviral regimen of ABT\u2010450\/r ombitasvir with\/without dasabuvir in subjects with mild moderate and severe renal impairment compared to subjects with normal renal function. In Proceedings of the AASLD 2014 Boston MA USA 7\u201311 November2014."},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","unstructured":"PockrosPJ ReddyKR MantryPSet al.Safety of Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end\u2010stage renal disease: The RUBY\u2010I\u2010Study. In Proceedings of the EASL 2015 Vienna Austria 22\u201326 April2015.","DOI":"10.1016\/S0168-8278(15)30147-1"},{"key":"e_1_2_6_25_1","unstructured":"RothD NelsonD BruchfeldAet al.C\u2010SURFER: Grazoprevir plus Elbasvir in treatment\u2010naive and treatment\u2010experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. In Proceedings of the EASL 2015 Vienna Austria 22\u201026 April2015."},{"key":"e_1_2_6_26_1","unstructured":"SaxenaV KoraishyFM.Safety and efficacy of sofosbuvir\u2010containing regimens in hepatitis C infected patients with reduced renal function: Real\u2010world experience from HCV\u2010target. In Proceedings of the EASL 2015 Vienna Austria 22\u201026 April2015."},{"key":"e_1_2_6_27_1","unstructured":"Bristol\u2013Myers Squibb.Japan approves first all\u2010oral interferon and ribavirin\u2010free hepatitis C treatment Daklinza (daclatasvir) and Sunvepra (asunaprevir) Dual Regimen [media release]. 7 July 2014http:\/\/news.bms.com\/press\u2010release\/japan\u2010approvesfirst\u2010all\u2010oral\u2010interferon\u2010and\u2010ribavirin\u2010free\u2010hepatitis\u2010c\u2010treatment\u2010dakl."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0279-4"},{"key":"e_1_2_6_29_1","unstructured":"Bristol\u2013Myers Squibb Company.Sunvepra Capsules (asunaprevir) Japanese Prescribing Information 2014."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160818033"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.998997"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12407","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:11:01Z","timestamp":1695978661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/1744-9987.12407"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12407","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]}}}